Wealth Enhancement Advisory Services LLC Acquires Shares of 2,089 BioNTech SE (NASDAQ:BNTX)

Wealth Enhancement Advisory Services LLC bought a new position in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 2,089 shares of the company’s stock, valued at approximately $238,000.

Several other hedge funds have also made changes to their positions in BNTX. Jones Financial Companies Lllp boosted its position in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. boosted its position in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE bought a new stake in BioNTech during the fourth quarter valued at about $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new stake in BioNTech during the fourth quarter valued at about $137,000. Finally, AlphaCentric Advisors LLC bought a new stake in BioNTech during the fourth quarter valued at about $168,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on BNTX. Citigroup reaffirmed a “buy” rating and set a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. HC Wainwright lowered their price target on BioNTech from $145.00 to $138.00 and set a “buy” rating for the company in a report on Monday. Morgan Stanley lowered their price target on BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Leerink Partners set a $112.00 price target on BioNTech in a report on Monday, June 2nd. Finally, The Goldman Sachs Group assumed coverage on BioNTech in a report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 price target for the company. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and an average target price of $137.86.

BioNTech Trading Down 0.2%

BioNTech stock opened at $106.33 on Tuesday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a market capitalization of $25.56 billion, a price-to-earnings ratio of -50.63 and a beta of 1.29. The stock has a 50-day moving average price of $101.37 and a 200 day moving average price of $107.89.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.